HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:

Title: Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer
Authors: Ken, Ito Browse this author
Satoshi, Yuki Browse this author
Hiroshi, Nakatsumi Browse this author
Kawamoto, Yasuyuki Browse this author →KAKEN DB
Harada, Kazuaki Browse this author
Nakano, Shintaro Browse this author
Saito, Rika Browse this author
Ando, Takayuki Browse this author
Sawada, Kentaro Browse this author
Yagisawa, Masataka Browse this author
Ishiguro, Atsushi Browse this author
Dazai, Masayoshi Browse this author
Iwanaga, Ichiro Browse this author
Hatanaka, Kazuteru Browse this author
Sato, Atsushi Browse this author
Matsumoto, Ryusuke Browse this author
Shindo, Yoshiaki Browse this author
Tateyama, Miki Browse this author
Muranaka, Tetsuhito Browse this author
Katagiri, Masaki Browse this author
Yokota, Isao Browse this author →KAKEN DB
Sakata, Yuh Browse this author
Sakamoto, Naoya Browse this author →KAKEN DB
Komatsu, Yoshito Browse this author →KAKEN DB
Keywords: Dysgeusia
Taste disorder
Gastrointestinal cancer
Zinc acetate hydrate
Issue Date: 1-Jun-2022
Publisher: Springer
Journal Title: Supportive Care in Cancer
Volume: 30
Issue: 6
Start Page: 5351
End Page: 5359
Publisher DOI: 10.1007/s00520-022-06936-4
Abstract: Purpose Dysgeusia is an adverse event caused by chemotherapy. Although retrospective studies have shown zinc administration improves dysgeusia, there have been no prospective studies. The present study examined effects of zinc therapy on dysgeusia in patients with gastrointestinal cancer. Methods This multicenter, prospective, observational study enrolled patients with dysgeusia during chemotherapy treatment. Patients received no intervention (control), polaprezinc p.o., or zinc acetate hydrate p.o., and serum zinc levels were measured at 0 (baseline), 6, and 12 weeks. Dysgeusia was assessed using CTCAE v5.0 and subjective total taste acuity (STTA) criteria using questionnaires at baseline and 12 weeks. Results From February 2020 to June 2021, 180 patients were enrolled from 17 institutes. There were no differences in mean baseline serum zinc levels among the groups (67.3, 66.6, and 67.5 mu g/dL in the no intervention, polaprezinc, and zinc acetate hydrate groups, respectively. P = 0.846). The changes in mean serum zinc levels after 12 weeks were - 3.8, + 14.3, and + 46.6 mu g/dL, and the efficacy rates of dysgeusia were 33.3%, 36.8%, and 34.6% using CTCAE and 33.3%, 52.6%, 32.7% using STTA in the no intervention, polaprezinc, and zinc acetate hydrate groups, respectively. The STTA scores improved in all groups, with significant improvement observed in the polaprezinc group compared with the no intervention group (P = 0.045). Conclusion There was no significant correlation between the degree of serum zinc elevation and improvement in dysgeusia, suggesting that polaprezinc, but not zinc acetate hydrate, was effective in improving chemotherapy-induced dysgeusia.
Type: article
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 - Hokkaido University